Navigation Links
ACORN Continues Success in Oncology Data Warehousing With Accumulation of Nearly 50 Million Data Observations
Date:6/16/2008

MEMPHIS, Tenn., June 16 /PRNewswire/ -- Accelerated Community Oncology Research Network(TM), an oncology-focused CRO and research network, announced today that its Oncology Data Warehouse has accumulated nearly 50 million data observations from over 110,000 oncology patients contained in its data warehouse. Integrating patient-reported outcomes (PROs), electronic medical records (EMR), claims data, and laboratory information systems, garnered from community oncology practices nationwide where 85% of cancer care is provided, the warehouse contains demographically diverse data, offering reliable information on treatments and outcomes to payers, financial institutions, pharmaceutical / biotech companies, and community oncology practices.

(Logo: http://www.newscom.com/cgi-bin/prnh/20071112/CLM151LOGO )

"Our data warehouse is now mature enough to support longitudinal or cross- sectional analyses comparing practice patterns, toxicity, and outcomes in large groups of patients undergoing treatment for a broad range of tumor types," according to Ed Stepanski, Ph.D., Chief Operating Officer. "Additionally, several years of archived PACE System PROs provide a critical component to our Oncology Data Warehouse, allowing us to systematically analyze patients' symptom burden and quality of life, making our warehouse unique among all oncology data repositories."

Analytic data from this large-scale oncology data repository has been presented at many major oncology-related conferences and published in peer- reviewed medical journals worldwide. Furthering the field of oncology health informatics, ACORN's data warehouse has been used in numerous projects that address quality of care, patients' quality of life, overall health outcomes and the cost of care.

"Determining the most effective and least toxic treatment regimens in actual clinical practice, as opposed to a clinical trial, is a valuable end result from the data warehouse," observes Steve Coplon, CEO. "ACORN will soon double the number of unique patients in the warehouse. The warehouse runs as close to real time as is needed for projects we conduct."

ACORN will exhibit at the annual Drug Information Association meeting in Boston, June 22-25, 2008. Senior level ACORN executives will be present to discuss ACORN's Oncology Data Warehouse as well as its CRO services, Guardian EDC, and network of community oncology practices. For additional information visit http://www.ACORNresearch.net or contact Liz Conway, Director of Marketing and Corporate Services, 901-259-0878.

Accelerated Community Oncology Research Network, Inc. (ACORN)

ACORN focuses on oncology exclusively. ACORN offers centralized clinical trial services, scientific analysis, and is a full-service Clinical Research Organization (CRO), providing contract and budgeting services; fostering accrual of subjects at the site level; collecting data and monitoring its accuracy; and working seamlessly with both trial sponsors and participating practices.

Contact Information:

Liz Conway

(901) 435-5570

lconway@sosacorn.com

http://www.ACORNresearch.net

Deborah D. Coble

901-683-0055x1312

dcoble@sosacorn.com


'/>"/>
SOURCE Accelerated Community Oncology Research Network, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. ACORN Presents Findings of Collaborative Metastatic Colorectal Cancer Research
2. ACORNs Oncology-focused Contract Research Organization Exceeds Projections
3. AlphaVax Continues to Expand the Use of Its Vaccine Platform
4. Replidyne Discontinues Phase III Trial
5. Update From Mipomersen Extended Dosing Study Continues to Show That Mipomersen Is Well Tolerated and Maintains Activity in Patients Treated for Up to 16 Months
6. Medarex Announces Ipilimumab Program Continues to Move Forward
7. Carpet One Floor & Home Continues Making Dramatic Strides in Funding Breast Cancer Research and Awareness
8. Nuvelo Announces Phase 2 SONOMA-3 Trial Did Not Meet Target Product Profile and Discontinues Alfimeprase Development
9. Phase I and Phase I/II DCVax(R)-Brain Data Continues to Show Significantly Improved Survival Rates for Brain Cancer Patients
10. Bone Mineral Content Continues to Increase in Obese Adolescents During Weight Loss
11. The OrthoGlide(TM) Medial Knee Implant Continues to be Accepted as an Alternative to Total Knee Replacement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... 2016  Labvantage Lx, a newcomer to the ... sexual enhancement product, EnduramenT. Setting a new standard ... a patented biomedical breakthrough molecule that promotes the ... responsible for many biological functions including erectile function. ... Forgoing the use of prescription medications, scientists working ...
(Date:2/8/2016)... 2016  Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) ... quarter and year-end 2015 results after the Nasdaq market ... host a live conference call and webcast to discuss ... afternoon, February 11, 2016 at 4:30 p.m. Eastern Time ... --> http://www.neurocrine.com . --> Participants can ...
(Date:2/8/2016)... 2016 --> ... "Ablation Technologies Market by Product (Radiofrequency, Ultrasound, Irreversible Electroporation, ... Surgery, Ophthalmology, Gynecology) - Global Forecasts to 2020", published ... the forecast period of 2015 to 2020. The market ... CAGR of 10.5% from 2015 to 2020. ...
Breaking Medicine Technology:
(Date:2/8/2016)... ... 2016 , ... The Association of Home Care Coding & ... Health and Hospice ICD-10 Transition Workgroup are working closely with the American Hospital ... to address concerns over the use of 'A' as the seventh character indicating ...
(Date:2/8/2016)... ... 08, 2016 , ... Guruji Mahendra Kumar Trivedi is offering 3 days of ... of his birthday on February 10th. During this time, people can achieve better ... over 250,000 people from over 40 different countries as an ÔÇťordinary man with an ...
(Date:2/7/2016)... Clarkston, Metamora, Michigan (PRWEB) , ... February 07, ... ... correct pelvic organ prolapse with the latest techniques and the most minimally invasive ... for pelvic organ prolapse, particularly after menopause. Other risk factors include surgery to ...
(Date:2/7/2016)... Scottsdale, AZ (PRWEB) , ... February 07, 2016 ... ... & Neck and Facial Plastics, has added Kybella® to his medical and surgical ... is a newly approved FDA injectable medication used as a non-surgical alternative for ...
(Date:2/6/2016)... ... , ... With the FCPX LUT: Summer pack from Pixel Film ... LUT is a Lookup Table that contains a mathematical formula for modifying an image. ... By manipulating each pixel, LUT's can change each color range differently, it gives the ...
Breaking Medicine News(10 mins):